# A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.

> **NCT06298071** · PHASE1 · RECRUITING · sponsor: **Shanghai Institute Of Biological Products** · enrollment: 36 (estimated)

## Conditions studied

- Gout

## Interventions

- **DRUG:** SIBP-R002
- **DRUG:** SIBP-R002
- **DRUG:** SIBP-R002
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT06298071
- **Lead sponsor:** Shanghai Institute Of Biological Products
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-03
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06298071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06298071, "A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06298071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*